Oncology Institute of Southern Switzerland / Istituto Oncologico della Svizzera Italiana

Research facility


Location: Bellinzona, Switzerland (CH) CH

ISNI: -

ROR: https://ror.org/01dpyn972

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Regional hyperthermia for soft tissue sarcoma–a survey on current practice, controversies and consensus among 12 European centers (2024) Roohani S, Ehret F, Beck M, Veltsista DP, Nadobny J, Zschaeck S, Abdel-Rahman S, et al. Journal article A patterns of care analysis of hyperthermia in combination with radio(chemo)therapy or chemotherapy in European clinical centers (2022) Ademaj A, Veltsista PD, Marder D, Haelg RA, Puric E, Brunner TB, Crezee H, et al. Journal article RESULTS OF THE IELSG32 TRIAL AT A MEDIAN FOLLOW-UP OF 88 MONTHS DEMONSTRATE THAT MATRIX FOLLOWED BY AUTOLOGOUS TRANSPLANT IS ASSOCIATED WITH EXCELLENT SURVIVAL AND NEUROTOLERABILITY IN PATIENTS WITH PRIMARY CNS LYMPHOMA (2021) Calimeri T, Cwynarski K, Pulczynski E, Fox CP, Schorb E, Steffanoni S, Foppoli M, et al. Conference contribution Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal L (2017) Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosee P, Binder M, et al. Journal article Short Peptide Vaccine Induces CD4+ T Helper Cells in Patients with Different Solid Cancers (2016) Gross S, Lennerz V, Gallerani E, Mach N, Boehm S, Hess D, Von Boehmer L, et al. Journal article Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial (2016) Ferreri AJM, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, et al. Journal article Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors (2014) Lennerz V, Gross S, Gallerani E, Sessa C, Mach N, Boehm S, Hess D, et al. Journal article